Brief: Helix Biopharma Corp. Provides Strategic Update On L-Dos47 Clinical Program
13/11/2018 22:15
Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. PROVIDES STRATEGIC UPDATE ON L-DOS47
CLINICAL PROGRAM
Source text for Eikon: ID:nGNX1TDp0M
Further company coverage: HBP.TO
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020